<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41023717</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Spirometry to manage asthma in children: study protocol for a randomised controlled trial (SPIROMAC).</ArticleTitle><Pagination><StartPage>373</StartPage><MedlinePgn>373</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-025-09104-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Asthma affects over 1 million children across the UK, and preventative treatment is guided subjectively by patient symptoms. Spirometry is an objective test of lung function and can be used in children to guide treatment. However, current guidelines do not indicate how asthma treatment should change in the context of changing spirometry results. This study will evaluate how spirometry can be used to guide asthma treatment and reduce the risk for asthma attacks in children.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This is a multi-centre, randomised controlled trial. Children aged 6-15&#xa0;years, who have a diagnosis of asthma and have had an exacerbation requiring oral or intravenous corticosteroids in the previous 12&#xa0;months, will be eligible. Exclusion criteria include being unable to provide spirometry measurement at baseline assessment, having another chronic respiratory condition and being currently treated with maintenance oral steroids or biologicals. Participants will be recruited in both primary and secondary care settings and will be randomised to either receive asthma treatment guided by spirometry plus symptoms (intervention group) or asthma treatment guided by symptoms only (standard care group). Within the spirometry group, treatment recommendations will be dependent on changes in spirometry measurements. Participants will attend assessments 3, 6, 9 and 12&#xa0;months post-randomisation, where treatment recommendations will be made. The primary outcome is the number of asthma attacks per participant requiring treatment with 1-7&#xa0;days of oral or intravenous corticosteroid over 12&#xa0;months, as recorded by the participant or parent. Secondary outcomes include time to first attack, any asthma attack, adverse events, dose of inhaled corticosteroids, asthma control and quality of life. Adherence to inhaled corticosteroid treatment is measured by an electronic logging device.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">This study will evaluate whether asthma treatment guided by spirometry will reduce future asthma attacks in children. Our findings may be relevant to national and international asthma guidelines.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ISRCTN, ISRCTN31849868. Registered on 01.07.2022. Prospectively registered.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Bell</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-9518-9296</Identifier><AffiliationInfo><Affiliation>Centre for Healthcare Randomised Trials, University of Aberdeen, Aberdeen, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sergenson</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-2956-0282</Identifier><AffiliationInfo><Affiliation>Centre for Healthcare Randomised Trials, University of Aberdeen, Aberdeen, UK. nicole.sergenson@abdn.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotton</LastName><ForeName>Seonaidh</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-7883-0608</Identifier><AffiliationInfo><Affiliation>Centre for Healthcare Randomised Trials, University of Aberdeen, Aberdeen, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emele</LastName><ForeName>Chukwuemeka David</ForeName><Initials>CD</Initials><Identifier Source="ORCID">0000-0003-1060-9963</Identifier><AffiliationInfo><Affiliation>Aberdeen Centre for Evaluation, University of Aberdeen, Aberdeen, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-8316-2616</Identifier><AffiliationInfo><Affiliation>Centre for Healthcare Randomised Trials, University of Aberdeen, Aberdeen, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aucott</LastName><ForeName>Lorna</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-6277-7972</Identifier><AffiliationInfo><Affiliation>Aberdeen Centre for Evaluation, University of Aberdeen, Aberdeen, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forrest</LastName><ForeName>Mark</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2395-8823</Identifier><AffiliationInfo><Affiliation>Centre for Healthcare Randomised Trials, University of Aberdeen, Aberdeen, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaillard</LastName><ForeName>Erol A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0003-0996-8133</Identifier><AffiliationInfo><Affiliation>Department of Respiratory Sciences, NIHR Biomedical Research Centre (Respiratory Theme), University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennington</LastName><ForeName>Erika J</ForeName><Initials>EJ</Initials><Identifier Source="ORCID">0000-0001-7834-1161</Identifier><AffiliationInfo><Affiliation>Asthma + Lung UK, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacLennan</LastName><ForeName>Graeme</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-1039-5646</Identifier><AffiliationInfo><Affiliation>Centre for Healthcare Randomised Trials, University of Aberdeen, Aberdeen, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinha</LastName><ForeName>Ian</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-7342-5523</Identifier><AffiliationInfo><Affiliation>Respiratory Unit, Alder Hey Children's Hospital, Liverpool, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vadiveloo</LastName><ForeName>Thenmalar</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5531-6289</Identifier><AffiliationInfo><Affiliation>Aberdeen Centre for Evaluation, University of Aberdeen, Aberdeen, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Neil W</ForeName><Initials>NW</Initials><Identifier Source="ORCID">0000-0002-8067-9660</Identifier><AffiliationInfo><Affiliation>Biostatistics and Health Data Science, University of Aberdeen, Aberdeen, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Steve</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8393-5060</Identifier><AffiliationInfo><Affiliation>Royal Aberdeen Children's Hospital, NHS Grampian, Aberdeen, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>NIHR129819</GrantID><Agency>Efficacy and Mechanism Evaluation Programme</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018927">Anti-Asthmatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001249" MajorTopicYN="Y">Asthma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013147" MajorTopicYN="Y">Spirometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018927" MajorTopicYN="Y">Anti-Asthmatic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="Y">Lung</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="Y">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Asthma</Keyword><Keyword MajorTopicYN="N">Child</Keyword><Keyword MajorTopicYN="N">Randomised controlled trial</Keyword><Keyword MajorTopicYN="N">Spirometry</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate {24}: The trial has ethical approval from West Midlands&#x2014;Black Country Research Ethics Committee (22/WM/0097), and central and local NHS R&amp;D approvals have been obtained. The study is co-sponsored by the University of Aberdeen and NHS Grampian. Consent is obtained from parents/carers, and (where appropriate) from the child. If the child does not provide written consent, they are asked to give verbal assent. Consent for publication {32}: Not applicable since there are no identifying images or other personal or clinical details of participants presented. Informed consent materials are available from the corresponding author. Competing interests {28}: All authors report grant funding paid to their institution from NIHR/MRC (Efficacy and Mechanism Evaluation, NIHR129819) for the SPIROMAC trial. EAG also reports investigator-led research grants from Gilead Sciences, Chiesi Limited and Propeller Health; research collaboration with Astra Zeneca, Helicon Health and Adherium (NZ) Limited; and speaker fees from Circassia Group and Sanofi.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41023717</ArticleId><ArticleId IdType="doi">10.1186/s13063-025-09104-1</ArticleId><ArticleId IdType="pii">10.1186/s13063-025-09104-1</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Asthma UK. Asthma facts and FAQs. 2020; Available at: https://www.asthma.org.uk/about/media/facts-and-statistics/ . Accessed 04/12, 2020.</Citation></Reference><Reference><Citation>Strachan DP. Repeatability of ventilatory function measurements in a population survey of 7 year old children. Thorax. 1989;44(6):474&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thx.44.6.474</ArticleId><ArticleId IdType="pubmed">2763257</ArticleId><ArticleId IdType="pmc">1020807</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo DK, Beardsmore CS, Roland D, Richardson M, Yang Y, Danvers L, et al. Lung function and asthma control in school-age children managed in UK primary care: a cohort study. Thorax. 2020;75(2):101&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2019-213068</ArticleId><ArticleId IdType="pubmed">31666388</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Initiative for Asthma. Global strategy for asthma management and prevention. https://ginasthma.org/gina-reports/ . Updated 2019. Accessed 07/26, 2019.</Citation></Reference><Reference><Citation>Fuhlbrigge AL, Kitch BT, Paltiel AD, Kuntz KM, Neumann PJ, Dockery DW, et al. FEV(1) is associated with risk of asthma attacks in a pediatric population. J Allergy Clin Immunol. 2001;107(1):61&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mai.2001.111590</ArticleId><ArticleId IdType="pubmed">11149992</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institute for Health and Care Excellence. Asthma: Diagnosis, monitoring and chronic asthma management. https://www.nice.org.uk/guidance/ng80 . Updated 2017. Accessed 01/28, 2018.</Citation></Reference><Reference><Citation>Papadopoulos NG, Arakawa H, Carlsen K, Custovic A, Gern J, Lemanske R, et al. International consensus on (ICON) pediatric asthma. Allergy. 2012;67(8):976&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1398-9995.2012.02865.x</ArticleId><ArticleId IdType="pubmed">22702533</ArticleId></ArticleIdList></Reference><Reference><Citation>National, Asthma Education and Prevention Program Expert panel report 3&#x2014;Guidelines for the diagnosis and management of asthma. https://www.nhlbi.nih.gov/files/docs/guidelines/asthsumm.pdf . Updated 2007. Accessed 01/02, 2018.</Citation></Reference><Reference><Citation>British Thoracic Society and Scottish Intercollegiate Guidelines Network. SIGN 158. The British guideline on the management of asthma. https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/ . Updated 2019. Accessed 07/27, 2019.</Citation></Reference><Reference><Citation>NICE (National Institute for Health and Care Excellence). Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN). https://www.nice.org.uk/guidance/ng245 . Updated 2024. Accessed 04/03, 2025</Citation></Reference><Reference><Citation>Reddel HK. Peak flow monitoring in clinical practice and clinical asthma trials. Curr Opin Pulm Med. 2006;12(1):75&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.mcp.0000198065.65704.08</ArticleId><ArticleId IdType="pubmed">16357583</ArticleId></ArticleIdList></Reference><Reference><Citation>Fielding S, Pijnenburg M, de Jongste JC, Pike KC, Roberts G, Petsky H, et al. Change in FEV(1) and Feno measurements as predictors of future asthma outcomes in children. Chest. 2019;155(2):331&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2018.10.009</ArticleId><ArticleId IdType="pubmed">30359613</ArticleId></ArticleIdList></Reference><Reference><Citation>Teach SJ, Gergen PJ, Szefler SJ, Mitchell HE, Calatroni A, Wildfire J, et al. Seasonal risk factors for asthma exacerbations among inner-city children. J Allergy Clin Immunol. 2015Jun;135(6):1465-73.e5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2014.12.1942</ArticleId><ArticleId IdType="pubmed">25794658</ArticleId><ArticleId IdType="pmc">4461505</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitch BT, Paltiel AD, Kuntz KM, Dockery DW, Schouten JP, Weiss ST, et al. A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest. 2004;126(6):1875&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.126.6.1875</ArticleId><ArticleId IdType="pubmed">15596687</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu AC, Gregory M, Kymes S, Lambert D, Edler J, Stwalley D, et al. Modeling asthma exacerbations through lung function in children. J Allergy Clin Immunol. 2012;130(5):1065&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2012.08.009</ArticleId><ArticleId IdType="pubmed">23021884</ArticleId><ArticleId IdType="pmc">3683131</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacharier LB, Strunk RC, Mauger D, White D, Lemanske RFJ, Sorkness CA. Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function. Am J Respir Crit Care Med. 2004Aug 15;170(4):426&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200308-1178OC</ArticleId><ArticleId IdType="pubmed">15172893</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G, et al. After asthma: redefining airways diseases. Lancet. 2018;391(10118):350&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)30879-6</ArticleId><ArticleId IdType="pubmed">28911920</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner SW. Uncertain role of spirometry in managing childhood asthma in the UK 2019. Arch Dis Child 2020 Sep;105(9):914. Epub 2019 Jul 3.</Citation></Reference><Reference><Citation>Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med. 2001Oct 15;164(8 Pt 1):1376&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.164.8.2101145</ArticleId><ArticleId IdType="pubmed">11704581</ArticleId></ArticleIdList></Reference><Reference><Citation>SPIROMAC Study website; Available at: https://w3.abdn.ac.uk/hsru/SPIROMAC/Public/Public/index.cshtml . Accessed 04/03, 2025</Citation></Reference><Reference><Citation>Turner S, Cotton SC, Emele CD, et al. Reducing asthma attacks in children using exhaled nitric oxide as a biomarker to inform treatment strategy: a randomised trial (RAACENO). Trials. 2019;20:573. https://doi.org/10.1186/s13063-019-3500-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-019-3500-7</ArticleId><ArticleId IdType="pubmed">31585544</ArticleId><ArticleId IdType="pmc">6778366</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrie L, Turner S, Cotton SC, Wood J, Morgan HM. A qualitative process evaluation within a clinical trial that used healthcare technologies for children with asthma-insights and implications. PLoS ONE. 2023Jan 5;18(1):e0280086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0280086</ArticleId><ArticleId IdType="pubmed">36603013</ArticleId><ArticleId IdType="pmc">9815588</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanojevic S, Wade A, Stocks J, Hankinson J, Coates AL, Pan H, et al. Reference ranges for spirometry across all ages: a new approach. Am J Respir Crit Care Med. 2008Feb 1;177(3):253&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200708-1248OC</ArticleId><ArticleId IdType="pubmed">18006882</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner S, Filipow N, Vermeulan F, Vael R, Frischer T, Changg A, Petsky H, Szefler S, Stanojevic S. How much change in FEV1 is associated with an increased risk of an asthma exacerbation? European Respiratory Society ;62(suppl 67):OA1436.</Citation></Reference><Reference><Citation>Filipow N, Turner S, Petsky HL, Chang AB, Frischer T, Szefler S, et al. Variability in forced expiratory volume in 1 s in children with symptomatically well-controlled asthmaThorax 2024 Nov 14;79(12):1145&#x2013;1150.</Citation></Reference><Reference><Citation>Schatz M, Sorkness CA, Li JT, Marcus P, Murray JJ, Nathan RA, et al. Asthma control test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006;117(3):549&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2006.01.011</ArticleId><ArticleId IdType="pubmed">16522452</ArticleId></ArticleIdList></Reference><Reference><Citation>Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res. 1996;5(1):35&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00435967</ArticleId><ArticleId IdType="pubmed">8901365</ArticleId></ArticleIdList></Reference><Reference><Citation>Dweik RA, Boggs PB, Erzurum SC, Irvin CG, Leigh MW, Lundberg JO, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applicationsAm J Respir Crit Care Med 2011 Sep 1;184(5):602&#x2013;615.</Citation></Reference><Reference><Citation>Vansteelandt S, Linder M, Vandenberghe S, Steen J, Madsen J. Mediation analysis of time-to-event endpoints accounting for repeatedly measured mediators subject to time-varying confoundingStat Med. 2019Oct 30;38(24):4828&#x2013;40.</Citation></Reference><Reference><Citation>NIHR Funding and Awards website; Available at: https://www.fundingawards.nihr.ac.uk/ . Accessed 04/04, 2025.</Citation></Reference><Reference><Citation>Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.05.00034805</ArticleId><ArticleId IdType="pubmed">16055882</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson D, Sergenson N, Bell V, Constable L, Wileman S. Site evaluations of trial training and recommendations for practice. ICTMC 2024 Abstract Book;121.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>